Renal impairment in patients with thromboembolic event: Prevalence and clinical implications: A systematic review of the literature;Niereninsuffizienz bei Patienten mit einem thromboembolischen Ereignis: Prävalenz und klinische Implikationen

Deutsche Medizinische Wochenschrift

Volumn 140, Issue 17, 2015, Pages e166-e174

  Wilke, Thomas ^a   Wehling, Martin ^b   Amann, Steffen ^c   Bauersachs, Rupert M ^d   Böttger, Björn ^a  

^a Hochschule Wismar   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Krankenhausapotheke Schwabing   (Germany)

^d KLINIKUM DARMSTADT   (Germany)

Author keywords

initial anticoagulation; prevalence renal insufficiency; renal impairment; thrombosis

Indexed keywords

ARTICLE; HUMAN; KIDNEY FAILURE; THROMBOEMBOLISM; BLEEDING; COMORBIDITY; EPIDEMIOLOGY; META ANALYSIS; MORTALITY; RISK ASSESSMENT; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

ANTICOAGULANT AGENT;

ANTICOAGULANTS; CAUSALITY; COMORBIDITY; HEMORRHAGE; HUMANS; RENAL INSUFFICIENCY; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84940025920     PISSN: 00120472     EISSN: 14394413     Source Type: Journal    
DOI: 10.1055/s-0041-103168     Document Type: Article

References (48)

1. Blix H. S., Viktil K. K., Moger T. A., Reikvam A. Use of renal risk drugs in hospitalized patients with impaired renal function - an underestimated problem? Nephrol Dial Transplant: 2006; 21 3164 3171
2. Deutsche Gesellschaft für Angiologie Diagnostik und Therapie der Venenthrombose und der Lungenembolie. AWMF-Leitlinien-Register Nr. 065/002. http://www.awmf.org/uploads/tx-szleitlinien/065-002-S2-Diagnostik-Therapie-Venenthrombose-Lungenembolie-2010-abgelaufen.pdf Letzter Zugriff am 27.07.2015
3. Moysidis T., Santosa F., Stallinger C., Kröger K. Cranial and non-cranial embolism: incidence in hospitalised patients in Germany. J Thromb Thrombolysis: 2013; 36 369 374
4. Bauersachs R. M. Use of anticoagulants in elderly patients. Thromb Res: 2012; 129 107 115
5. Clark N. P. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency. Thromb Res: 2008; 123 01 S58 S61
6. Ellis M. H., Hadari R., Tchuvrero N. et al. Hemorrhagic complications in patients treated with anticoagulant doses of a low molecular weight heparin (enoxaparin) in routine hospital practice. Clin Appl Thromb Hemost: 2006; 12 199 204
7. Falgá C., Capdevila J. A., Soler S. et al. Clinical outcome of patients with venous thromboembolism and renal insufficiency. Findings from the RIETE registry. Thromb Haemost: 2007; 98 771 776
8. Hoffmann P., Keller F. Increased major bleeding risk in patients with kidney dysfunction receiving Enoxaparin: a meta-analysis. Eur J Clin Pharmacol: 2012; 68 757 765
9. Kooiman J., den Exter P. L., Cannegieter S. C. et al. Impact of chronic kidney disease on the risk of clinical outcomes in patients with cancer-associated venous thromboembolism during anticoagulant treatment. J Thromb Haemost: 2013; 11 1968 1976
10. Lim W., Dentali F., Eikelboom J. W., Crowther M. A. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency. Ann Intern Med: 2006; 144 673 684
11. Monreal M., Falgá C., Valle R. et al. Venous thromboembolism in patients with renal insufficiency: findings from the RIETE Registry. Am J Med: 2006; 119 1073 1079
12. Parikh A. M., Spencer F. A., Lessard D. et al. Venous thromboembolism in patients with reduced estimated GFR: a population-based perspective. Am J Kidney Dis: 2011; 58 746 755
13. Spencer F. A., Gore J. M., Reed G. et al. Venous thromboembolism and bleeding in a community setting. The Worcester Venous Thromboembolism Study. Thromb Haemost: 2009; 101 878 885
14. Thorevska N., Amoateng-Adjepong Y., Sabahi R. et al. Anticoagulation in hospitalized patients with renal insufficiency: a comparison of bleeding rates with unfractionated heparin vs Enoxaparin. Chest: 2004; 125 856 863
15. Tsai J., Abe K., Boulet S. L. et al. Predictive accuracy of 29-comorbidity index for in-hospital deaths in US adult hospitalizations with a diagnosis of venous thromboembolism. PLoS One: 2013; 8 e70061
16. Botticelli Investigators Efficacy and safety of the oral direct factor Xa inhibitor apixaban for symptomatic deep vein thrombosis. The Botticelli DVT dose-ranging study. J Thromb Haemost: 2008; 6 1313 1318
17. Bauersachs R., Berkowitz S. D., Brenner B. et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med: 2010; 363 2499 2510
18. Moher D., Liberati A., Tetzlaff J. et al. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Ann Intern Med: 2009; 151 264 269
19. Mahmoodi B. K., Gansevoort R. T., Næss I. A. et al. Association of mild to moderate chronic kidney disease with venous thromboembolism: pooled analysis of five prospective general population cohorts. Circulation: 2012; 126 1964 1971
20. Folsom A. R., Lutsey P. L., Astor B. C. et al. Chronic kidney disease and venous thromboembolism: a prospective study. Nephrol Dial Transplant: 2010; 25 3296 3301
21. Kumar G., Sakhuja A., Taneja A. et al. Pulmonary embolism in patients with CKD and ESRD. Clin ���� Am Soc Nephrol: 2012; 7 1584 1590
22. Wattanakit K., Cushman M. Chronic kidney disease and venous thromboembolism: epidemiology and mechanisms. Curr Opin Pulm Med: 2009; 15 408 412
23. Cook D., Crowther M., Meade M. et al. Deep venous thrombosis in medical-surgical critically ill patients: prevalence, incidence, and risk factors. Crit Care Med: 2005; 33 1565 1571
24. Königsbrügge O., Lötsch F., Zielinski C. et al. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res: 2014; 134 44 49
25. Kurtal H., Schwenger V., Azzaro M. et al. Clinical Value of Automatic Reporting of Estimated Glomerular Filtration Rate in Geriatrics. Gerontology: 2009; 55 288 295
26. Nutescu E. A., Spinler S. A., Wittkowsky A., Dager W. E. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings. Ann Pharmacother: 2009; 43 1064 1083
27. Trujillo-Santos J., Schellong S., Falga C. et al. Low-molecular-weight or unfractionated heparin in venous thromboembolism: the influence of renal function. Am J Med: 2013; 126 425 434
28. Al-Dorzi H. M., Al-Heijan A., Tamim H. M. et al. Renal failure as a risk factor for venous thromboembolism in critically Ill patients: a cohort study. Thromb Res: 2013; 132 671 675
29. Boettger B., Wehling M., Bauersachs R. M. et al. Initial anticoagulation therapy in patients with venous thromboembolism and impaired renal function: results of an observational study. J Public Health: 2014; 22 89 99
30. Tiryaki F., Nutescu E. A., Hennenfent J. A. et al. Anticoagulation therapy for hospitalized patients: patterns of use, compliance with national guidelines, and performance on quality measures. Am J Health Syst Pharm: 2011; 68 1239 1244
31. Leizorovicz A., Siguret V., Mottier D. et al. Safety profile of tinzaparin versus subcutaneous unfractionated heparin in elderly patients with impaired renal function treated for acute deep vein thrombosis: the Innohep® in Renal Insufficiency Study (IRIS). Thromb Res: 2011; 128 27 34
32. Lai S., Barbano B., Cianci R. et al. The risk of bleeding associated with low molecular weight heparin in patients with renal failure. G Ital Nefrol: 2010; 27 649 654
33. Samama M. M. Use of low-molecular-weight heparins and new anticoagulants in elderly patients with renal impairment. Drugs Aging: 2011; 28 177 193
34. Crowther M., Lim W. Low molecular weight heparin and bleeding in patients with chronic renal failure. Curr Opin Pulm Med: 2007; 13 409 413
35. Nagge J., Crowther M., Hirsh J. Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med: 2002; 162 2605 2609
36. Bauersachs R. M. New oral anticoagulants and chronic kidney disease. Internist (Berl): 2012; 53 1431 1444
37. Ageno W., Riva N., Noris P. et al. Safety and efficacy of low-dose fondaparinux (1.5mg) for the prevention of venous thromboembolism in acutely ill medical patients with renal impairment: the FONDAIR study. J Thromb Haemost: 2012; 10 2291 2297
38. Bauersachs R., Schellong S. M., Haas S. et al. CERTIFY: prophylaxis of venous thromboembolism in patients with severe renal insufficiency. Thromb Haemost: 2011; 105 981 988
39. Dentali F., Riva N., Gianni M. et al. Prevalence of renal failure and use of antithrombotic prophylaxis among medical inpatients at increased risk of venous thromboembolic events. Thromb Res: 2008; 123 67 71
40. Salomon L., Deray G., Jaudon M. C. et al. Medication misuse in hospitalized patients with renal impairment. Int J Qual Health Care: 2003; 15 331 335
41. Cook L. M., Kahn S. R., Goodwin J., Kovacs M. J. Frequency of renal impairment, advanced age, obesity and cancer in venous thromboembolism patients in clinical practice. J Thromb Haemost: 2007; 5 937 941
42. Barras M. A., Kirkpatrick C. M., Green B. Current dosing of low-molecular-weight heparins does not reflect licensed product labels: an international survey. Br J Clin Pharmacol: 2010; 69 520 528
43. Sevestre M. A., Belizna C., Durant C. et al. Compliance with recommendations of clinical practice in the management of venous thromboembolism in cancer: the CARMEN study. J Mal Vasc: 2014; 39 161 168
44. Chambers J. T., Chambers S. K., Schwartz P. E. Correlation between measured creatinine clearance and calculated creatinine clearance in ovarian cancer patients. Gynecol Oncol: 1990; 36 66 68
45. Levey A. S., Bosch J. P., Lewis J. B. et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med: 1999; 130 461 470
46. Lim W. H., Lim E. M., McDonald S. Lean body mass-adjusted Cockcroft and Gault formula improves the estimation of glomerular filtration rate in subjects with normal-range serum creatinine. Nephrology (Carlton): 2006; 11 250 256
47. Michels W. M., Grootendorst D. C., Verduijn M. et al. Performance of the Cockcroft-Gault, MDRD, and new CKD-EPI formulas in relation to GFR, age, and body size. Clin J Am Soc Nephrol: 2010; 5 1003 1009
48. Cook D. J., Douketis J., Arnold D., Crowther M. A. Bleeding and venous thromboembolism in the critically ill with emphasis on patients with renal insufficiency. Curr Opin Pulm Med: 2009; 15 455 462